全文获取类型
收费全文 | 235101篇 |
免费 | 14874篇 |
国内免费 | 989篇 |
专业分类
耳鼻咽喉 | 2524篇 |
儿科学 | 5991篇 |
妇产科学 | 4415篇 |
基础医学 | 29292篇 |
口腔科学 | 4321篇 |
临床医学 | 24052篇 |
内科学 | 49560篇 |
皮肤病学 | 3221篇 |
神经病学 | 23655篇 |
特种医学 | 10110篇 |
外国民族医学 | 13篇 |
外科学 | 37007篇 |
综合类 | 2536篇 |
现状与发展 | 1篇 |
一般理论 | 177篇 |
预防医学 | 16516篇 |
眼科学 | 5532篇 |
药学 | 15480篇 |
1篇 | |
中国医学 | 319篇 |
肿瘤学 | 16241篇 |
出版年
2023年 | 1335篇 |
2022年 | 2191篇 |
2021年 | 5336篇 |
2020年 | 3043篇 |
2019年 | 5052篇 |
2018年 | 6048篇 |
2017年 | 4441篇 |
2016年 | 4847篇 |
2015年 | 5730篇 |
2014年 | 8348篇 |
2013年 | 11244篇 |
2012年 | 17274篇 |
2011年 | 18006篇 |
2010年 | 10066篇 |
2009年 | 9310篇 |
2008年 | 15862篇 |
2007年 | 16652篇 |
2006年 | 16194篇 |
2005年 | 16052篇 |
2004年 | 15100篇 |
2003年 | 13785篇 |
2002年 | 13182篇 |
2001年 | 1928篇 |
2000年 | 1426篇 |
1999年 | 2002篇 |
1998年 | 2783篇 |
1997年 | 2212篇 |
1996年 | 1922篇 |
1995年 | 1762篇 |
1994年 | 1526篇 |
1993年 | 1492篇 |
1992年 | 977篇 |
1991年 | 923篇 |
1990年 | 782篇 |
1989年 | 741篇 |
1988年 | 676篇 |
1987年 | 612篇 |
1986年 | 636篇 |
1985年 | 678篇 |
1984年 | 908篇 |
1983年 | 786篇 |
1982年 | 1034篇 |
1981年 | 964篇 |
1980年 | 835篇 |
1979年 | 464篇 |
1978年 | 514篇 |
1977年 | 448篇 |
1976年 | 419篇 |
1975年 | 314篇 |
1974年 | 310篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Periannan Kuppusamy Penghai Wang Michael Chzhan Jay L. Zweier 《Magnetic resonance in medicine》1997,37(4):479-483
The application of electron paramagnetic resonance imaging (EPRI) to obtain information from biological samples has been limited by the lack of ideal single line radical labels. The commonly used nitroxides exhibit multiple lines causing either hyperfine-based limitations in the maximum obtainable image resolution or hyperfine-based artifacts in the reconstructed image. The use of a novel single-line triarylmethyl paramagnetic label that enables marked enhancement in image quality and resolution is reported. This label exhibits a single line EPR spectrum that is sharp (linewidth ~60 mG in the absence of oxygen) and relatively stable in tissues. The potential of this label in enabling high resolution EPR imaging of biological samples was demonstrated in a series of phantoms and isolated biological organs such as the rat kidney. The images demonstrate that resolutions better than 100 μm could be obtained at L-band on samples of up to 20 mm in size. 相似文献
102.
103.
104.
105.
106.
INLANDER, CHARLES B., LEVIN, LOWELL B., AND WEINER, E.D. Medicine on Trial: The Appalling Story of Medical Ineptitude and the Arrogance that Overlooks It. 相似文献
107.
Jeffrey A. Gray Stephen N. Mitchell Michael H. Joseph Grigory A. Grigoryan Sharon Dawe Helen Hodges 《Drug development research》1994,31(1):3-17
Data are reviewed, largely from experiments in the authors'laboratory, that suggest three modes of action of systemic nicotine in producing three different types of effect upon behavior and cognitive function. (1) Preexposure of a stimulus without consequence makes it harder subsequently to form associations to that stimulus, a form of selective attention known as latent inhibition. Latent inhibition is blocked by nicotine, an effect that is apparently mediated by a nicotine-induced increase in dopamine release in the nucleus accumbens. (2) A single dose of nicotine proactively increases the partial reinforcement extinction effect measured several weeks later: that is, resistance to extinction is decreased by nicotine in animals that have been trained on a continuous reinforcement schedule, and increased in animals trained on a partial reinforcement schedule. This effect appears to be due to increased synthesis of tyrosine hydroxylase in the cell bodies of noradrenergic neurons in the locus coeruleus, followed by axonal transport to the hippocampus and increased synthesis and release of noradrenaline in that structure. (3) Nicotine improves vigilance in animals with cognitive deficits due to destruction of the forebrain cholinergic projection system, either as a consequence of excitotoxic lesions of the nuclei of origin of this system or after prolonged alcohol consumption; and also in human subjects with Alzheimer's disease (in which this system undergoes degeneration). This effect is most likely due to an action at denervated cholinergic synapses in the hippocampus and neocortex. © 1994 Wiley-Liss, Inc. 相似文献
108.
Eileen J. Martin Kiran S. Panickar Michael A. King Malgorzata Deyrup Bruce E. Hunter Geehuan Wang Edwin M. Meyer 《Drug development research》1994,31(2):135-141
The potential cytoprotective actions of a novel nicotinic agent 2,4-dimethoxybenzilidene anabaseine (DMXB) were investigated in differentiated PC12 cells and transected rat septal cholinergic neurons in vivo. In NGF-differentiated PC12 cells, removal of both NGF and serum led to cell loss, a reduced % of cells expressing neurites, the release of lactate dehydrogenase, and a decrease in total cellular protein. Cell loss was apparent within 24 h, and remained constant between 4–8 days post-NGF removal. NGF alone (100 ng/ml), DMXB (10 μM), but not nicotine (10 μM), prevented these cell and neurite losses. DMXB-induced cytoprotection was blocked by 1 μM mecamylamine. DMXB (1 mg/kg, ip) injected twice but not once per day protected cholinesterase-staining septal neurons from retrograde degeneration following unilateral fimbrial transections. The twice per day DMXB injection-protocol also decreased cell roundness among cholinesterase-staining cells in the lesioned septal hemisphere compared to saline-injected animals. These studies suggest that DMXB may exert cytoprotective activity in NGF-sensitive neuronal populations. © 1994 Wiley-Liss, Inc. 相似文献
109.
110.
Total global biodiversity is estimated at between 3 and 500 × 106 species of prokaryote and eukaryote organisms spread across 70 or more phyla. The marine macrofauna alone are estimated between 0.5 and 30 × 106 species and represents a broader range of taxonomic diversity than that found in the terrestrial environment, which has been the traditional source of natural products. With a typical eukaryote possessing 50,000 genes, the global marine macrofauna are the source of 2.5 × 1010 to 1.5 × 1012 primary products and an associated extensive range of secondary products. However, only a few thousand novel compounds from marine organisms have been described. These compounds have proven unique in chemical and pharmacological terms but, as yet, no therapeutic agents have resulted. Given a broader drug discovery strategy, and facilitated by technological advances, it is predicted that the characterisation of marine chemical diversity will be accelerated. Strategies for drug discovery from the virtually untapped chemical diversity of marine organisms are discussed. © 1994 Wiley-Less, Inc. 相似文献